GlassScriptPhysician profile
Mahmoud Sarmini
NPI 1770505786
$523.18
in general payments reported to CMS, 2019-2025
7 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.78 · 2020: $36.41 · 2023: $112 · 2024: $187 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $201.52 | 2024-2025 | Radicava |
| Alnylam Pharmaceuticals INC. | $92.88 | 2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $71.92 | 2023 | Kesimpta |
| Amgen INC. | $47.78 | 2019-2025 | Uplizna |
| Virtus Pharmaceuticals LLC | $40.26 | 2023 | Levorphanol Tartrate |
| Ethicon US, LLC | $36.41 | 2020 | |
| Amylyx Pharmaceuticals, INC. | $32.41 | 2024 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Sarmini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.